Valsartan brand name
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Valsartan Brand Name: A Comprehensive Overview
Introduction to Valsartan
Valsartan is a widely used angiotensin II receptor antagonist, commonly referred to as an ARB (angiotensin receptor blocker). It is primarily prescribed for the treatment of hypertension, heart failure, and to improve survival rates post-myocardial infarction . This article explores the various brands of valsartan, their bioequivalence, and their market presence.
Popular Brands of Valsartan
Diovan® by Novartis
Diovan® is one of the most recognized brands of valsartan, produced by Novartis. It is often used as a reference product in bioequivalence studies due to its established efficacy and safety profile . Diovan® has been extensively studied and is considered a benchmark for comparing other valsartan formulations.
Valzan® by Unspecified Manufacturer
Valzan® is another notable brand of valsartan. A study comparing Valzan® with Diovan® concluded that Valzan® exhibits a pharmacokinetic profile comparable to Diovan®, indicating that it is well-formulated and bioequivalent. This makes Valzan® a reliable alternative to Diovan®.
Krka's Valsartan
Krka, a leading pharmaceutical company in Central, Eastern, and South-Eastern Europe, has been producing high-quality valsartan for over 15 years. Their valsartan products, including monoform and single-pill combinations, are known for their high quality and have not been affected by recalls due to impurities. Krka's valsartan has gained significant trust among healthcare professionals and patients.
Bioequivalence Studies
Comparative Studies in Different Populations
Several studies have been conducted to compare the bioequivalence of different valsartan brands. For instance, a study in India compared two branded generic formulations with a reference product and found that one of the test formulations was bioequivalent to the reference, while the other was not. Similarly, a study in Algeria compared a local brand with TAREG (Novartis) and found that the two were not bioequivalent under fasting conditions.
Methodologies and Findings
Bioequivalence studies typically involve randomized, crossover designs where healthy volunteers receive different formulations of valsartan. Blood samples are collected and analyzed to determine pharmacokinetic parameters such as Cmax (maximum concentration), Tmax (time to reach Cmax), and AUC (area under the curve). These parameters are then statistically compared to assess bioequivalence .
Market Presence and Economic Considerations
Availability and Economic Impact
The availability of multiple brands of valsartan ensures that patients have access to effective treatment options even if one brand is unavailable. Studies have shown that different brands of valsartan meet the required specifications and are manufactured following GMP and cGMP guidelines, making them interchangeable based on economic conditions.
Trust and Quality Assurance
Brands like Krka's valsartan have built strong trust among physicians, pharmacists, and patients due to their consistent quality and absence of impurity-related recalls. This trust is crucial for ensuring continuous and effective treatment for hypertension and related conditions.
Conclusion
Valsartan is a critical medication for managing hypertension and heart-related conditions. Various brands, including Diovan®, Valzan®, and Krka's valsartan, have been studied for their bioequivalence and market presence. These studies ensure that patients have access to safe, effective, and economically viable treatment options. The continuous availability and high quality of these brands contribute significantly to the effective management of hypertension worldwide.
Sources and full results
Most relevant research papers on this topic